Frequency of adenomyosis in specimen from the operation. [ Time Frame: postoperative ] [ Designated as safety issue: No ]

Frequency of adenomyosis in specimen from the operation. Values are given as n (%).

Frequency and grade of genital prolapse [ Time Frame: 60 and 120 months after procedure ] [ Designated as safety issue: No ]

Frequency and grade of genital prolapse 60 and 120 months after procedure(POP-Q). Values are given as n (%) Type of prolapse is specified according to POP-Q Staging Criteria 0-IV and as cystocele, rectocele, enterocele, vault prolapse or combined prolapse.

Volume of uterine corpus preoperative, location and size of fibromas, Weight of the removed uterus/uterine corpus. [ Time Frame: Pre- and perioperative ] [ Designated as safety issue: No ]

Volume of the uterine corpus preoperative (cm3). Values are given as median (range) or mean (sd). Size and location of fibromas preoperative (cm). Values are given as median (range) or mean (sd), and is specified by location. Weight of the removed uterus/uterine corpus (g). Values are given as median (range) or mean (sd).

Sample: 62 consecutive premenopausal women referred to the department for hysterectomy on the basis of a benign condition. The expected mean pain reduction (m) in the LSH group: 3.32, sd (s): 2.71.24 A difference in mean pain reduction (d) equal to 1 sd is considered a clinically important improvement (standardised difference d/s=1). Number of women required (power 90 % and a level of significance 0.05): 62 patients.

Women with a concomitant condition requiring uni- or bilateral oophorectomy.

Postmenopausal women.

Women with no dysmenorrohea/cyclic pelvic pain (<1 on a 10-point visual analogue scale).

Women with deep infiltrating endometriosis.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01289314